Assoc. Prof. Dr. Murat Ayhan

2001 Kızıltepe Anadolu Lisesi

2007 Dicle Üniversitesi Tıp Fakültesi — Études de médecine

2014 İstanbul Medeniyet Üniversitesi Göztepe Eğitim ve Araştırma Hastanesi — Médecine interne; Formation spécialisée

2021 Kartal Şehir Hastanesi — Oncologie médicale; Formation spécialisée

2023 — Oncologie médicale; Maître de conférences

Oncologie : Adıyaman Üniversitesi Eğitim ve Araştırma Hastanesi

Oncologie : Liv Hospital Vadistanbul

İstanbul Ümraniye Eğitim ve Araştırma Hastanesi — Oncologie médicale

Liv Hospital Ulus — Oncologie médicale

Cancers du sein, du poumon et colorectaux

Cancers gynécologiques et urogénitaux

Oncologie moléculaire

Traitements personnalisés et ciblés

Société turque d’oncologie médicale (TTOD)

European Society for Medical Oncology (ESMO)

Étude de phase II comparant le GDC-9545 à une monothérapie endocrine dans le cancer du sein avancé HR-positif/HER2-négatif

Étude de phase III du GDC-0077 avec palbociclib et fulvestrant dans le cancer du sein avancé avec mutation PIK3CA

Étude de phase Ib/III comparant l’atézolizumab sous-cutané et intraveineux dans le cancer bronchique non à petites cellules avancé

Étude multicentrique de l’ajout d’apalutamide à la radiothérapie et à un agoniste de la LHRH dans le cancer de la prostate hormonosensible à haut risque

Étude de biomarqueurs dans le cancer urothélial avancé avec altérations du gène FGFR — 42756493BLC0002

Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.

Ayhan M, Odabas H, Turan N, et all . Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.

Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.

Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.

Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitisation With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.

Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749

Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.

Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.

Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.

Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.

Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.

Cil I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.

Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.

Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.

Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.

Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.

Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.

Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.

Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.

Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.

Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.

Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.

Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30

Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., Doi: 10.5455/annalsmedres.2021.07.490

Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.

Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus. 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.

Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720

Hedefe yönelik ajanların ilaç etkilesimleri ve yan etkileri, Bölüm adı:(Küçük molekül tirozin kinaz inhibitörleri; ROS-1 hedefli tedaviler (Krizotinib, Seritinib)) (2021)., AYHAN MURAT, Türkiye Klinikleri Tıp Bilimleri Dergisi, Editör:Mehmet Aliustaoglu, Basım sayısı:1, Sayfa Sayısı 92, ISBN:978-625-401- 466-6, Türkçe

Gastrointestinal stromal tümörler ve nöroendokrin tümörlere yaklasım, Bölüm adı:(Primer gastrointestinal dısı nöroendokrin tümörlerde medikal yaklasım) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editör: Anılır Ender, Basım sayısı:1, Sayfa Sayısı 382, ISBN: 9786052585719 , Türkçe

Iç hastalıkları acilleri, Bölüm adı:(Onkolojik aciller) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Akademik Yayıncılık, Editör:Serdar Olt, Basım sayısı:1, Sayfa Sayısı 232, ISBN:978-625-8324-66-2, Türkçe

Physicians' cancer chemotherapy drug manual 2020, Bölüm adı:(Klinik pratikte yaygın kemoterapi rejimleri) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Tıp Bilimleri Dergisi, Editör: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Basım sayısı:1, Sayfa Sayısı 772, ISBN:978-625-401-290- 7, Türkçe (Kitap Tercümesi)